Solriamfetol for Binge Eating Disorder
This study is testing if solriamfetol can help adults with binge eating disorder (BED). Researchers want to see if taking solriamfetol (either 150 mg or 300 mg) once a day for 12 weeks can reduce the number of binge eating episodes compared to a placebo (an inactive pill). You could be eligible if you are 18 to 55 years old and have a primary diagnosis of BED. The study aims to enroll 450 participants. The current recruitment status is unclear.
- Study design
- This is a Phase 3, randomized, double-blind study, meaning participants are randomly assigned to receive solriamfetol or placebo, and neither you nor your doctor will know which you are receiving. It plans to include 450 participants.
- What's involved
- You would take solriamfetol tablets or a placebo once daily for 12 weeks. You must also provide written informed consent.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at 12 weeks, which is the duration of the treatment period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
At a glance
Conditions
Where it's being run
45 sites across 18 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change from Baseline to Week 12 in number of binge eating episodes12 weeks